Boomers Should Buy These High-Yield Dividend August Bargains Hand-Over-Fist
At 24/7 Wall St., five high-yield dividend stocks are highlighted as “August bargains” after dips tied to earnings misses or weaker guidance. Altria (MO) yields 6.24%, with Q2 2026 adjusted EPS $1.48 vs $1.50-$1.54. Comcast (CMCSA) yields 5.58% and has a $4.6B Q2 free cash flow. Pfizer (PFE) yields 6.77%, with Q2 2026 adjusted EPS 77c on $15.03B revenue. UBS and Rosenblatt rate MO and CMCSA “Buy” with $79 and $31 targets.
How this was made
The 30-second read
Why it matters
It provides specific Q2 earnings/guidance datapoints for MO, CMCSA, and PFE and adds a corporate action detail for CMCSA (planned spin). However, it is largely an income-investor promotional roundup rather than a first-report of a new catalyst.
Market read
For traders, the actionable elements are the cited earnings/guidance datapoints and CMCSA’s planned spin, but the article’s “August bargains” framing limits incremental decision value.
What to watch
Dividend sustainability and payout coverage are not quantified here; traders may need to verify free-cash-flow durability and whether guidance misses/ARPU declines persist into subsequent quarters.
Background
The piece surveys five high-yield dividend stocks after Q2 earnings, emphasizing dips tied to earnings misses or guidance concerns and the possibility of higher rates.
Ticker impact
Altria shares dropped after Q2 2026 earnings showed a narrow adjusted EPS miss ($1.48 vs $1.50-$1.54) despite slightly beating revenue.
Near-term trading likely remains sentiment-driven around earnings/guidance expectations, but the yield and buyback narrative can cushion downside.
This is a promotional “bargains” piece, but it includes concrete Q2 EPS miss details and mentions a $2.4B repurchase plan, which can influence dip-buying behavior.
Comcast fell sharply despite Q2 beating estimates, citing broadband subscriber losses and pressure on ARPU, plus a planned NBCUniversal and Sky spin.
Stock reaction risk stays elevated while subscriber/ARPU trends remain weak, but the spin-off could improve medium-term valuation expectations.
The text provides specific operational drivers (broadband ARPU -3.1% YoY) and a concrete tax-free spin timeline, both relevant for traders, though the article is still an editorial roundup.
Pfizer’s Q2 2026 adjusted earnings beat (77 cents vs 68 cents) and it raised the low end of full-year revenue guidance, while discussing a potential GLP-1 launch.
If investors focus on the raised guidance and GLP-1 optionality, the stock could see continued support, but margin/operating-income concerns remain a counterweight.
The article includes specific Q2 results and guidance change, which are actionable inputs, but it does not provide new regulatory/clinical trial endpoints beyond general “potential launch” language.
Market effects
Highlights investor preference for high-yield defensives and telecom cash-flow stories when rate expectations shift.
Primarily US-focused large-cap income names; limited direct regional spillover implied.
Comcast’s Sky/NBCUniversal spin and Pfizer’s global pharma pipeline are globally relevant, but the article provides no new cross-border regulatory or deal catalyst.
Counterpoint
The “bargains” framing may underweight fundamental trend risk: subscriber losses for CMCSA and margin/operating-income shrink for PFE, plus valuation/profit-taking for MO.
Key entities
- companyAltria
Q2 2026 adjusted EPS miss ($1.48 vs $1.50-$1.54) and dividend/buyback narrative.
- companyComcast
Q2 beat but shares down; broadband ARPU pressure and planned NBCUniversal and Sky tax-free spin.
- companyPfizer
Q2 adjusted earnings beat (77 cents vs 68 cents) and raised low end of full-year revenue guidance; GLP-1 launch potential mentioned.
